Ligand Pharmaceuticals (LGND) Share-based Compensation Growth (3y) (2013 - 2025)
Ligand Pharmaceuticals (LGND) Share-based Compensation Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 244.08% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -50.27% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -0.04% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 38.45% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.63% |
| Sep 30, 2025 | -16.38% |
| Jun 30, 2025 | 450.27% |
| Mar 31, 2025 | -47.92% |
| Dec 31, 2024 | 55.48% |
| Sep 30, 2024 | 15.86% |
| Jun 30, 2024 | -4.55% |
| Mar 31, 2023 | 42.73% |
| Dec 31, 2022 | -90.77% |
| Sep 30, 2022 | 58.80% |
| Jun 30, 2022 | -81.20% |
| Mar 31, 2022 | 26.51% |
| Dec 31, 2021 | -493.46% |
| Sep 30, 2021 | 252.34% |
| Jun 30, 2021 | 137.21% |
| Mar 31, 2021 | 9.01% |
| Dec 31, 2020 | 48.22% |
| Mar 31, 2020 | -38.17% |
| Dec 31, 2019 | 6.58% |
| Sep 30, 2019 | -22.81% |